101 results about "Leprosy" patented technology

Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.

The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereofwherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

The invention discloses a leprosy tree bacteria root nursery sock growing method, comprising the procedures of bacteria root agent preparation, seedling process, bacteria root agent inoculation, replanting and vaccination of seedling tubes. The invention is vaccinated with mycorrhizal fungi, which improves stress resistance and adaptability of leprosy trees. And the bacteriorhiza agent vaccination method has the advantages of little energy consumption, convenient employment, excellent production increase and extensive application scope, promotes the growing of leprosy trees and provides large numbers of high grade root bacteria seedlings for industrialized plantation of leprosy trees.

The invention provides a bagged external washing ointment for assisting treatment of gynecologic inflammation and itchiness. The ointment is characterized in that the formula comprises the following raw materials according to weight percentage: 15-35 percent of dandelion, 10-25 percent of sophora flavescens ait, 5-25 percent of common cnidium fruit, 5-25 percent of cortex phellodendri, 15-35 percent of honeysuckle and 3-10 percent of calcined alum. The preparation method comprises the following steps of removing foreign impurities, cleaning, drying, grinding, sieving and bagging. The ointment has the effects of clearing away heat and toxic material, diminishing inflammation, treating urinary tract infection, treating toxic heat, curing leprosy and sore, removing erosion and itchiness of vulva, curing trichomonas vaginitis, eliminating pustules, reducing swelling, curing phlegm and persistent pain, relieving itching, curing trauma infection, relieving prickly heat, astringing, stopping bleeding, growing flesh and the like.

The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase activity, and a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE. Preferably, the multifunctional enzyme has substantial anti cell-cell adhesion activity. Preferably, the multifunctional enzyme has substantial homology with the krill multifunctional enzyme. These enzymes are useful for treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including autoimmune disease and cancer. Additionally, the invention relates to a method of purifying the multifunctional enzyme, and to a preparation of essentially purified multifunctional enzyme.

The invention discloses a Chinese preparation for treating burn without leaving scars, which is prepared from the following components in part by weight: giant knotweed 190, garden burnet root 160, rhubarb 135, propolis 145, Hemiboea subcapitata C. B. Clarke 85, cactus 90, Jatropha curcas skin 30, twotooth achyranthes root 85, radix pseudo-ginseng 60, Azolla imbricata 55, beautyberry 35, dragon's blood 30, amur corktree bark 30, pagodatree pod 28, cicada shell 15, musk 0.7, borneol 7.5 and 95 percent alcohol for pharmaceutical purposes 4,500. The preparation has the characteristics of stopping blood, constricting, relieving pains and itching, achieving antibacterial effect, quickly healing wounds and avoiding leaving scars and the like. The preparation can treat burn simply and quickly, does not require strict sterilization operation and can be applied after the wound surface is cleaned simply. The preparation can make epithelial tissue and collagen issue of the wound surface grow in proportion, repair the wound surface more completely and obviously reduce pigmentation and scar generation.

The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereofwherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Dapsone and related sulfones are known to have therapeutic activity against leprosy, dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposiís sarcoma, pneumocystis carinií (pneumonia), subcorneal pustular dermatosis and cystic acne, in patients in need of such therapy. These sulfones are also known to have therapeutic activity against memory loss in patients in need of such therapy, including patients suffering from Alzheimer's disease and related neurodegenerative disorders. It has now been found that new, modified-release formulations of dapsone and related sulfones may also be used that decrease side effects and increase effectiveness of the drugs. New methods are disclosed utilizing certain formulations of dapsone and related sulfones that improve the therapeutic index of said drugs. Side effects of these drugs are known to those skilled in the art and include, but are not restricted to anorexia, psychosis, agranulocytosis, peripheral neuritis, hemolysis, methemoglobinemia, nausea, vomiting, headache, dizziness, tachycardia, nervousness, insomnia and skin disorders. Modified-release (as defined herein) formulations of dapsone have now been found to avoid some or all of these side effects, and to have more efficacy on potency.

The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereofwherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

The invention belongs to the technical field of medicine and particularly relates to a synthetic method of the medicine for treating leprosy. The synthetic method is characterized in that phthalic anhydride and glutamic acid are used as raw materials, one-pot operation is performed, direct synthesis is performed, and then a finished product is obtained after purification. Yield is improved from 50% to about 80%. Simultaneously, N, N-dimethylformamide and other solvents are adopted in a condensation step. Compared with a solvent pyridine used in the original process, environment pollution is reduced, and cost is saved. Dimethyl sulfoxide is used as a solvent during purification, and purified mother liquor is recycled. Compared with the solvent N, N-dimethylformamide adopted by the original process, the low-toxicity solvent is used, the problem that the original process is much in impurities and unqualified in residual solvent is solved, and the purified mother liquor is recycled so as to reduce product cost further.

The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereofwherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

The invention discloses a rheumatoid-arthritis-related single-gene single nucleotide polymorphism site and an application thereof. According to the technical scheme disclosed by the invention, the application is an application of substances for detecting polymorphism or genotype of rs1050501 in human genome in preparation of products for screening patients with rheumatoid arthritis, and an application of substances for detecting polymorphism or genotype of rs1050501 in human genome in preparation of products for predicting the illness states of the patients with rheumatoid arthritis. The substances for detecting the polymorphism or genotype of rs1050501 can be combined with other substances (such as other substances for detecting leprosy-related single nucleotide polymorphism or genotype) to prepare the products for screening patients with leprosy or predicting the illness states of the patients with rheumatoid arthritis.

Disclosed are benzothiazin derivatives of formula (I), preparation methods therefore, and treatment methods employing such compounds as antibacterial agents in treating infectious diseases of mammals caused by bacteria, especially diseases like tuberculosis and leprosy caused by mycobacteria:wherein R1, R2, R3, R4, R5, and R6, and other variables enumerated under one or more of R1, R2, R3, R4, R5, and R6 are as defined.

Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.

The invention provides flatstem milkvetch seed oral liquid for improving immunity. The flatstem milkvetch seed oral liquid is prepared from the following raw materials in parts by weight: 10-50 parts of flatstem milkvetch seed, 10-20 parts of mulberry, 10-20 parts of Chinese angelica, 10-20 parts of prepared rhizome of rehmannia, 10-20 parts of astragalus membranaceus, 10-20 parts of glossy privet fruit, 10-20 parts of semen cuscutae, 10-20 parts of rhizoma polygonati, 10-20 parts of radix codonopsis, 10-20 parts of poria cocos, 10-20 parts of fructus alpiniae oxyphyllae, 10-20 parts of human placenta, 10-20 parts of dogwood, 10-20 parts of raspberry, 10-20 parts of radix paeoniae rubrathe (unpeeled) root of common peony, 10-20 parts of bighead atractylodes rhizome, 10-20 parts of dendrobium, 10-20 parts of Chinese magnoliavine fruit, and 10-20 parts of rhizoma acori graminei. The oral liquid uses the flatstem milkvetch seed as raw materials, and the traditional Chinese medicines which nourish liver and kidney, have moderate mouth feel and are easily accepted by people are added, so that the immunity can be obviously improved, and the situations that sub-health crowds are easy to have a cold, the eyes of the sub-health crowds are acerb, the sleep quality of the sub-health crowds is not high, and the sub-health crowds have splenic asthenia and weakness can be better improved; the oral liquid can alleviate the symptoms of reduced appetite, dry mouth, drinking and urine, deficiency of the kidney, soreness and weakness of waist and knees, impotence and seminal emission, tinnitus and blurring vision, premature graying hair, weak health and emaciation, leprosy and ringworm diseases; the oral liquid does not have toxicity or stimulus, so that the oral liquid is suitable for people to take for a long term.

The invention discloses a kit for detecting HLA-B*1301 gene. The kit comprises the following components: 2*PCR Mix, a target gene detection mix, a reference genes detection mix, a positive reference group pMED-B*1301 and deionized water, wherein the gene detection mix comprises 5'-ggtctcacatcatccagagg-3', and a downstream primer 5'ttcctctgcgacgtcgcg-3'; and the reference genes detection mix comprises an upstream primer beta-F:5'- ctgggacgacatggagaaaa-3', and a downstream primer beta-R:5'- aaggaaggctggaagagtgc-3'. As HLA-B*1301 has close relationship with DHS and has the potential to be the biomarker for predicting dapsone allergic syndrome morbidity of Chinese people, by researching and developing the kit to detect the prediction marker HLA-B*1301 of the dapsone allergic syndrome morbidity, the dapsone allergic syndrome morbidity of leprosy patients can be monitored, therefore, the kit has important clinical significance.

Methods for making and using substrates of deamidase of prokaryotic ubiquitin-like protein (Dop) are described herein. More particularly, modified prokaryotic ubiquitin-like protein (Pup) and functional fragments thereof that serve as exemplary Dop substrates are described and encompassed herein. Screening methods to identify modulators of Dop and Pup activity and use of modulators identified thereby are also described. Methods of using modulators that are identified as inhibitors of Dop and Pup activity for treating diseases / conditions associated with Mycobacterium tuberculosis (Mtb) infection, such as tuberculosis and leprosy, are also envisioned.

The invention relates to a pharmaceutical composite for treating skin itch. The pharmaceutical composite is prepared from the following medicinal raw materials in parts by weight: 15-40 parts of anti-inflammatory and analgesic bolus powder, 65-155 parts of rehmannia, 30-70 parts of astragalus mongholicus, 65-155 parts of rhizoma smilacis glabrae, 30-70 parts of cortex dictamni, 30-70 parts of Chinese angelica, 60-100 parts of Xanthium canadense, 60-100 parts of wild chrysanthemum flower, 15-40 parts of processed agkistrodon, 65-155 parts of caltrop, 60-100 parts of red-rooted salvia, 30-70 parts of red paeony root, 60-100 parts of kuh-seng, 30-70 parts of toasted spina date seed and 20-50 parts of liquorice. The pharmaceutical composite has the functions of clearing away heat and dampness, activating the circulation of blood and removing stasis, repelling wind and cooling blood, eliminating swelling and removing toxins and killing worms and is applicable to skin itch, chronic mange, rash and blister, scrotum wet and itch, wind leprosy and inflammatory skin which are caused by rash and inflammatory skin diseases.

The present invention relates to insect resistant transgenic cotton plants. In particular, the present invention relates to a specific event designated COT102. The invention also relates to polynucleotides unique to COT102 events, plants comprising said polynucleotides, and methods of detecting COT102 events. This COT102 event showed a new genotype containing 2 expression cassettes. The first cassette contains a suitable promoter for expression in plants operably linked to a gene encoding a VIP3A insecticidal toxin useful for controlling broad-spectrum leprosy and a suitable polyadenylation signal. Pteroptera insect pests. The second box contains genes that can be used as selectable markers when expressed.

The invention discloses a Chinese patent medicine ointment for external use on skin, which is prepared from the following raw materials in parts by weight: 18-25 parts of rhizoma atractylodis, 10-15 parts of hemp seed, 2.5-4.8 parts of long-noded pit viper, 18-22 parts of black bean, 10-14 parts of radix ophiopogonis, 6-12 parts of plantago asiatica, 10-17 parts of cyrtomium rhizome and 8-17 parts of garlic bulb core. Compared with the existing medicines, the medicine disclosed by the invention relieves the disease symptoms in a short time and realizes a remarkable curative effect; the long-noded pit viper has the functions of dispelling wind, dredging collaterals and stopping spasm and is applied to rheumatism and obstinate arthralgia, numbness and muscular constriction, wry mouth in stroke, hemiplegia, convulsion and spasm, tetanus, leprosy scabies, scrofula and malignant sore; the radix ophiopogonis has the functions of improving immunologic functions and inhibits multiple kinds of bacteria; the garlic bulb core has the functions of sterilization and itching relief; and through the cooperation of multiple medicines, the effects of inhibiting psoriasis relapse, relieving pruritus and increasing the healing speed are realized.

The present invention relates to novel benzothiazin derivatives and their use as antibacterial agents in infectious diseases of mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and leprosy caused by mycobacteria.The present invention aims at the generation of new compounds with activity against mycobacteria as potential new tuberculosis drugs to overcome problems concerning resistance and drug intolerance.The solution of the present invention is a compound of the formula Iwherein R1 and R2 are, independently each from other, NO2, CN, CONR7R8, COOR9, CHO, halogen, NR7R8, SO2NR7R8, SR9, OCF3, mono-, di or trifluoromethyl;R3 and R4 are, independently each from other, H, a saturated or unsaturated, linear or branched aliphatic radical having 1-7 chain members, cycloalkyl having 3-6 carbon atoms, benzyl, SR9, OR9;R5 and R6 are, independently each from other, a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-8 chain members, cycloalkyl having 3-6 carbon atoms, phenyl, or R5 and R6 together represent a bivalent radical —(CR92)m—, or R5 and R6 together represent bivalent radicals:wherein m is 1-4, or represent bivalent radicals a saturated or unsaturated mono or polyheterocycles with heteroatoms N, S, O and substituted by (R10)x, wherein x is 1-4;R7, R8 and R9 are, independently each from other H or a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-7 chain members, mono-, di or trifluoromethyl, halogen, phenyl, or R3 and R4 together represent a bivalent radical —(CH2)n— wherein n is 2-7;R10 is H or a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-7 chain members, NO2, NR7R8, CN, CONR7R8, COOR9, CHO, halogen, SO2NR7R8, SR9, OR9, OCF3, mono-, di or trifluoromethyl, benzyl or phenyl.

The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereofwherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

The present invention relates to the use of compounds with a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, for the preparation of a medicament for preventing and / or treating mycobacterial infections such as tuberculosis and leprosy, to pharmaceutical compositions comprising them in combination with an antibiotic that is activatable via the EthA pathway, to compounds having a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, to pharmaceutical compositions comprising them and to their use as medicaments, especially medicaments for preventing and / or treating mycobacterial infections such as tuberculosis and leprosy.

The invention provides a dapsone-containing gel preparation and a preparation method thereof and belongs to the new technical field of medicines. The effective ingredient of the gel preparation is dapsone which is a sulfone type bacteriostatic agent, and the gel preparation has a sterilization effect when used in a large-dosage manner, has been used for treating leprosy clinically previously and is found that the gel preparation can also be used for treating nodular acne. A penetration enhancer is preferably selected for the gel preparation, so that the gel preparation has a good penetration property and a high deep sterilization function, can clear deep acne, is convenient to use, attractive in appearance and easy to clean and has no irritation to skin.

The invention discloses application of single-nucleotide-polymorphism rs55882956 in screening of Hansen's disease sufferers. The technical scheme protected by the invention is as follows: application of substances for detecting polymorphism or genotype of rs55882956 in a human genome in preparation of products for screening the Hansen's disease sufferers and application of the substances for detecting the polymorphism or genotype of the rs55882956 in the human genome in the preparation of products for detecting single nucleotide polymorphism related to Hansen's disease. The substances for detecting the polymorphism or genotype of the rs55882956 and other substances (such as substances for detecting other single nucleotide polymorphisms or genotypes related to the Hansen's disease) can be combined together so as to prepare products for screening the Hansen's disease sufferers.

The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereofwherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1 or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

The present invention discloses an efficient psoriasis vulgaris treating ointment, which is made from the following raw materials, by weight: 8-15 parts of radix sophorae flavescentis, 15-20 parts of stellera chamaejasme, 8-12 parts of cortex dictamni, 20-25 parts of zaocys dhumnades, 5-10 parts of indigo naturalis, 8-15 parts of lithospermum erythrorhizon, 20-28 parts of coix seed, and 80-150 parts of vaseline. According to the present invention, the drug can be used for the psoriasis vulgaris treating, the recurrence rate is reduced after using the drug of the present invention, the effect is high, and the skin itching and pain is reduced; the radix sophorae flavescentis has effects of heat clearing, dampness eliminating, insect disinfestation and dieresis, and is used for treatment of dysentery caused by heat, hematochezia, jaundice, uroschesis, leukorrhea with reddish discharge, vulvar swelling, vulvar itching, eczema, damp sore, skin itching, scall and leprosy; the zaocys dhumnades has effects of wind-evil dispelling, collateral dredging and convulsion relieving, and is used for treatment of rheumatism obstinate arthralgia, leprosy scall and scrofula ulcer; and the multiple drugs are matched so as to improve the treatment effect.

The invention discloses a method for directly regenerating leaf discs of Jatropha curcas. It selects annual Jatropha curcas leaves in the greenhouse as explants and inoculates them in the medium to directly induce adventitious buds; the medium is MS basic medium with 30g·L-1 sucrose, 4-8g·L-1 agar, 0.2 -2.0mg·L-1TDZ, 0.1-1.5mg·L-1IBA, 0.05-3mg·L-1BA, 0.5-8mg·L-1 Sodium Nitroprusside; culture method: first cultivate in dark for 10-14d, then switch to light Cultivate under conditions for 14-16 days; finally, the induced adventitious buds are cultured for elongation, and then transplanted after rooting culture. Adventitious bud induction rate is as high as 88%. The invention aims at providing a method for efficiently regenerating Jatropha leaf discs for gene improvement and tissue culture of Jatropha curcas. In order to realize the genetic transformation of Jatropha curcas, lay the foundation for rapid propagation, and promote the industrial development of Jatropha curcas.

The invention relates to a novel ointment for treating a microorganism infection skin disease and a preparation process thereof. The novel ointment for treating the microorganism infection skin disease consists of the following materials in part by mass: 0.1 to 0.3 part of trivalent silver ion compound, 0.2 to 0.4 part of keratinase, 0.5 to 5 parts of water-soluble keratin, 2 to 3 parts of composite vitamin and 94.3 to 98.7 parts of white petroleum jelly. The preparation process particularly comprises the following steps of: grinding 0.1 to 0.3 part of trivalent silver ion compound, 0.2 to 0.4 part of keratinase, 0.5 to 5 parts of water-soluble keratin and 2 to 3 parts of composite vitamin into powder; and adding 94.3 to 98.7 parts of white petroleum jelly into the powder and uniformly mixing the mixture. The ointment has the effects of rapidly sterilizing and relieving itching, expelling toxin and removing rot, and repairing skin. The ointment is suitable for treating and protecting a local skin disease caused by microorganism infection, such as fugal infection of hand and foot, tinea corporis, tinea cruris and onychomycosis (ringworm of the nails) caused by fungi, erysipelas and leprosy caused by bacteria, chicken pox, flat wart and herpes caused by virus and the like.